Solutions for gluten-related disorders
Targeted enzymatic digestion of gluten immunogenic peptides
AMYRA
Biotech AG
AMYRA Biotech AG
AMYRA Biotech AG is a private Swiss joint stock company based in Basel.
The multidisciplinary team brings together complementary expertise in drug development, biotechnology, immunology, medicine and business.
AMYRA collaborates intensively with universities, research institutes, industry partners and healthcare professionals.
AMYRA's mission is to deliver safe and effective therapeutics for the prevention of gluten-related health disorders.
AMYRA's mission is to deliver safe and effective therapeutics for the prevention of gluten-related health disorders.
A unique approach
AMYRA Products
Foundation
Scientific research has shown that partially digested gluten fragments, known as gluten immunogenic peptides (GIPs) trigger an autoimmune response in genetically predisposed people, namely celiac disease.
GIPs also play a role in the immune pathology of non-celiac gluten sensitivity, a clinical syndrome distinct from celiac disease.
AMYRA has developed a unique technology able to target GIPs in the intestine, where the pathology of celiac disease and non-celiac gluten sensitivity takes place.
AMYRA’s novel exopeptidase combinations have demonstrated
rapid and complete digestion of GIPs down to physiologically harmless amino-acids.
development
Latest Updates
2022
AMYRA will be presenting its latest data at the upcoming International Celiac Disease Symposium in Sorrento.
AMYRA has partnered with the Center of Drug Absorption and Transport (Greifswald University Hospital) for a first in human proof of concept study later this year.
